Skip to content

Price / book at other companies

Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
LQD
Liquidia CorporationLQDA
30.6×+5.3×
United Therapeutics logo
United TherapeuticsUTHR
4.4×+2.4×

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.47B+152%
Enterprise value$2.45B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×
Current ratio24.8×+9.4×

Where this comes from

Calculated from Trevi Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s price / book?
Trevi Therapeutics, Inc. (TRVI) reported price / book of 8.9× in Q1 2026.
How has Trevi Therapeutics, Inc.'s price / book changed year-over-year?
Trevi Therapeutics, Inc.'s price / book increased by 45.5% year-over-year, from 6.1× to 8.9×.
What is the long-term trend for Trevi Therapeutics, Inc.'s price / book?
Over 5 years (2020 to 2025), Trevi Therapeutics, Inc.'s price / book has grown at a 38.4% compound annual growth rate (CAGR), from 1.7× to 8.8×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.